Scholarlink

Background <p>Immune checkpoint blockade (ICB) therapy demonstrates significant efficacy across multiple malignancies, yet resistance remains prevalent. Recent studies have repositioned the clinically approved antiepileptic drug stiripentol (STP) as a potent lactate dehydrogenase A inhibitor that effectively disrupts tumor metabolic reprogramming, thereby reinstating tumor control. Despite its promising antineoplastic activity, the direct impact of STP on immune cells and its potential synergy with anti-PD-1 antibodies remain unexplored.</p> Methods <p>We used an orthotopic 4T1 breast cancer model to evaluate whether STP remodels the immunosuppressive tumor microenvironment and enhances anti-PD-1 efficacy. Tumor growth was monitored, and immune cell profiles in tumors and blood were analyzed by flow cytometry. Lactate levels and chemokine expression in tumor tissue were also assessed. In vitro, the effects of STP on 4T1 cell proliferation and lactate secretion, bone marrow-derived myeloid-derived suppressor cell (MDSC) differentiation and suppressive function, and macrophage polarization were evaluated.</p> Results <p>The combination of STP and anti-PD-1 synergistically suppressed 4T1 tumor growth, reduced the infiltration of immunosuppressive MDSCs and M2-like tumor-associated macrophages, and reactivated CD8⁺ T cells. STP inhibited 4T1 cell proliferation and lactate secretion in a concentration-dependent manner. Furthermore, STP directly reprogrammed MDSCs by inducing MHC II⁺ cell differentiation and attenuating their T cell suppressive capacity via downregulation of immunosuppressive genes. STP also drove M2-to-M1 macrophage repolarization. Importantly, STP exhibited no direct T cell-activating effects.</p> Conclusions <p>Our work establishes STP as a potent remodeler of the immunosuppressive tumor microenvironment that synergizes with anti-PD-1 therapy, providing a novel strategy to overcome ICB resistance.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Stiripentol directly attenuates immunosuppression of tumor-infiltrating myeloid cells to potentiate anti-PD-1 efficacy

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年2月28日

查看全文
  • Zhiqi Xie,
  • Kexin Wang,
  • Jiayi Liu,
  • Ziyi Hong,
  • Yuanzhen Jin,
  • Linying Wang,
  • Masashi Tachibana,
  • Jian Liu,
  • Meihua Lin,
  • Zeren Shen,
  • Jinjin Shao

摘要

Background

Immune checkpoint blockade (ICB) therapy demonstrates significant efficacy across multiple malignancies, yet resistance remains prevalent. Recent studies have repositioned the clinically approved antiepileptic drug stiripentol (STP) as a potent lactate dehydrogenase A inhibitor that effectively disrupts tumor metabolic reprogramming, thereby reinstating tumor control. Despite its promising antineoplastic activity, the direct impact of STP on immune cells and its potential synergy with anti-PD-1 antibodies remain unexplored.

Methods

We used an orthotopic 4T1 breast cancer model to evaluate whether STP remodels the immunosuppressive tumor microenvironment and enhances anti-PD-1 efficacy. Tumor growth was monitored, and immune cell profiles in tumors and blood were analyzed by flow cytometry. Lactate levels and chemokine expression in tumor tissue were also assessed. In vitro, the effects of STP on 4T1 cell proliferation and lactate secretion, bone marrow-derived myeloid-derived suppressor cell (MDSC) differentiation and suppressive function, and macrophage polarization were evaluated.

Results

The combination of STP and anti-PD-1 synergistically suppressed 4T1 tumor growth, reduced the infiltration of immunosuppressive MDSCs and M2-like tumor-associated macrophages, and reactivated CD8⁺ T cells. STP inhibited 4T1 cell proliferation and lactate secretion in a concentration-dependent manner. Furthermore, STP directly reprogrammed MDSCs by inducing MHC II⁺ cell differentiation and attenuating their T cell suppressive capacity via downregulation of immunosuppressive genes. STP also drove M2-to-M1 macrophage repolarization. Importantly, STP exhibited no direct T cell-activating effects.

Conclusions

Our work establishes STP as a potent remodeler of the immunosuppressive tumor microenvironment that synergizes with anti-PD-1 therapy, providing a novel strategy to overcome ICB resistance.